High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir - Institut Pierre Louis d'Epidémiologie et de Santé Publique Accéder directement au contenu
Article Dans Une Revue Antiviral Research Année : 2021

High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir

Résumé

Varicella-zoster virus (VZV) resistance to current antiviral drugs, that all target the viral DNA polymerase, represents a growing concern, notably among immunocompromised patients. Amenamevir, a novel antiviral that inhibits the VZV helicase-primase (HP) complex, is approved in Japan for the treatment of herpes zoster. In this study, we describe the low natural polymorphism of VZV HP complex (interstrain identity >99.7% both at nucleotide and amino acid levels) among 44 VZV clinical isolates. This work enabled to settle the maps of natural polymorphisms of VZV HP complex and to provide the genotypic tools for the monitoring of the emergence of VZV resistance to amenamevir in patients.
Fichier principal
Vignette du fichier
Pacreau et al. - 2021 - High conservation of varicella-zoster virus helica.pdf (683.09 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03390674 , version 1 (21-10-2021)

Identifiants

Citer

Marie-Liesse Pacreau, Olivier Bomme, Sonia Burrel, David Boutolleau. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir. Antiviral Research, 2021, 195, pp.105189. ⟨10.1016/j.antiviral.2021.105189⟩. ⟨hal-03390674⟩
33 Consultations
69 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More